




已閱讀5頁,還剩12頁未讀, 繼續(xù)免費閱讀
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)
文檔簡介
TheAntihypertensiveandLipid LoweringTreatmenttoPreventHeartAttackTrial ALLHATstudyoverviewDouble blind randomizedtrialtodeterminewhethertheoccurrenceoffatalCHDornonfatalMIislowerforhigh riskhypertensivepatientstreatedwithneweragents amlodipine lisinopril ordoxazosin comparedwithadiuretic chlorthalidone Cohort42 418patients 55yearsold from623sitesinNorthAmericaStage1or2hypertension1additionalriskfactorforCHDComparisonsbetweenchlorthalidoneandamlodipineandchlorthalidoneandlisinoprilhavebeenreportedtogether excludingthedoxazosinarm n 9 062 whichwasterminatedearly ALLHATResearchGroup JAMA 2002 288 2981 2997 www hypertensiononline org CHD coronaryheartdisease MI myocardialinfarction ALLHATStudyDesign n 13 8542 235 16 1 stoppeddrug Chlorthalidonen 15 255 Amlodipinen 9 048 Randomizedn 42 418 n 15 255339 2 2 losttofollow up80 0 5 refusedfollow up n 9 048200 2 2 losttofollow up58 0 6 refusedfollow up n 6 2101 873 30 2 stoppeddrug n 9 054218 2 4 losttofollow up58 0 6 refusedfollow up n 8 2151 357 16 5 stoppeddrug n 3 7691 052 27 9 stoppeddrug YEAR1 n 8 1581 842 22 6 stoppeddrug n 3 6051 399 38 8 stoppeddrug Lisinopriln 9 054 YEAR5 ALLHATResearchGroup JAMA 2002 288 2981 2997 www hypertensiononline org Intent to TreatAnalysis Doxazosinn 9 062 Discontinuedearlyat3 3yrs ALLHATEndpoints PrimaryendpointCompositeoffatalcoronaryheartdisease CHD ornonfatalmyocardialinfarction MI Otherpredefinedendpointsall causemortalitystrokecombinedCHD nonfatalMI CHDdeath coronaryrevascularization hospitalizedanginacombinedcardiovasculardisease combinedCHD stroke lowerextremityrevascularization treatedangina fatal hospitalized treatedcongestiveheartfailure hospitalizedoroutpatientperipheralarterialdiseaseother renal ALLHATResearchGroup JAMA 2002 288 2981 2997 www hypertensiononline org ALLHATBaselineCharacteristics ALLHATResearchGroup JAMA 2002 288 2981 2997 www hypertensiononline org BP bloodpressureCHD coronaryheartdisease ALLHATMeanSystolicandDiastolicBloodPressureDuringFollow up SystolicBP mmHg Follow up yrs DiastolicBP mmHg Chlorthalidone Amlodipine Lisinopril Chlorthalidone Amlodipine Lisinopril ALLHATResearchGroup JAMA 2002 288 2981 2997 Copyright 2002 AmericanMedicalAssociation www hypertensiononline org SBP systolicbloodpressureDBP diastolicbloodpressure Comparedtochlorthalidone DBPsignificantlylowerinamlodipinegroup 1mmHg Comparedtochlorthalidone SBPsignificantlyhigherinamlodipine 1mmHg andlisinopril 2mmHg groups ALLHATBPControlledto 140 90mmHg Lisinopril Amlodipine Chlorthalidone www hypertensiononline org ALLHATResearchGroup JAMA 2002 288 2981 2997 PatientswithBP 140 90mmHg P 0 001foramlodipinevschlorthalidone P 0 001forlisinoprilvschlorthalidone ALLHATTreatmentandBloodPressureControl 6mos 1yr 3yr 5yr 1Drug 2Drugs 3Drugs Patients CushmanWC etal JClinHypertens 2002 4 393 405 www hypertensiononline org Average ofdrugs 1 4 1 7 2 0 1 3 ALLHATPrimaryOutcomebyTreatmentGroup CumulativeFatalCHDandNonfatalMIeventrate Timetoevent yrs 0 1 2 3 4 5 6 1525590489054 7 No atRiskChlorthalidoneAmlodipineLisinopril 1447785768535 1382082188123 1310278437711 1136268246662 634038703832 295618781770 209215195 Chlorthalidone Amlodipine Lisinopril www hypertensiononline org ALLHATResearchGroup JAMA 2002 288 2981 2997 Copyright 2002 AmericanMedicalAssociation 0 5 1 2 0 5 1 2 ALLHATCHDDeathandNonfatalMI www hypertensiononline org Favorslisinopril Favorschlorthalidone Favorsamlodipine Favorschlorthalidone ALLHATResearchGroup JAMA 2002 288 2981 2997 Copyright 2002 AmericanMedicalAssociation 0 5 1 2 0 5 2 ALLHATAll CauseMortality www hypertensiononline org Favorslisinopril Favorschlorthalidone Favorsamlodipine Favorschlorthalidone 1 ALLHATResearchGroup JAMA 2002 288 2981 2997 Copyright 2002 AmericanMedicalAssociation 0 5 2 0 5 2 ALLHATCombinedCVDisease www hypertensiononline org Favorsamlodipine Favorschlorthalidone Favorslisinopril Favorschlorthalidone 1 1 ALLHATResearchGroup JAMA 2002 288 2981 2997 Copyright 2002 AmericanMedicalAssociation ALLHATStrokebyTreatmentGroup 0 1 2 3 4 5 6 1525590489054 7 No atRiskChlorthalidoneAmlodipineLisinopril 1451586178543 1393482718172 1330979497784 1157069376765 638538453891 321718131828 567506949 Cumulativeeventrate Chlorthalidone Amlodipine Lisinopril Timetoevent yrs www hypertensiononline org ALLHATResearchGroup JAMA 2002 288 2981 2997 Copyright 2002 AmericanMedicalAssociation 0 5 1 2 0 5 2 ALLHATStroke www hypertensiononline org Favorsamlodipine Favorschlorthalidone Favorslisinopril Favorschlorthalidone 1 ALLHATResearchGroup JAMA 2002 288 2981 2997 Copyright 2002 AmericanMedicalAssociation ALLHATHeartFailurebyTreatmentGroup 0 1 2 3 4 5 6 1525590489054 7 No atRiskChlorthalidoneAmlodipineLisinopril 1452885358496 1389881858096 1322478017689 1151167856698 636937753789 301617801837 384210313 Cumulativeeventrate Chlorthalidone Amlodipine Lisinopril Timetoevent yrs www hypertensiononline org P 0 001forchlorthalidonevsamlodipineandchlorthalidonevslisinopril ALLHATResearchGroup JAMA 2002 288 2981 2997 Copyright 2002 AmericanMedicalAssociation 0 5 2 0 5 2 ALLHATHeartFailure www hypertensiononline org Favorsamlodipine Favorschlorthalidone Favorslisinopril Favorschlorthalidone 1 1 ALLHATResearchGroup JAMA 2002 288 2981 2997 Copyright 2002 AmericanMedicalAssociation ALLHATConclusions BettercontrolofsystolicBPwasachievedwithchlorthalidonethanwithamlodipineorlisinoprilTherewerenodifferencesinriskforCHDdeath nonfatalMIbetweenchlorthalidoneandamlodipineorlisinoprilInsecondaryendpoints chlorthalidonewasassociatedwithlowerriskfo
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 科技創(chuàng)新團(tuán)隊的組建計劃
- 商超零售常態(tài)化疫情防控工作措施
- 2025-2025學(xué)年北師大版七年級歷史教學(xué)計劃
- 風(fēng)電項目施工文明管理措施分析
- 2025-2030中國石子整形機(jī)行業(yè)發(fā)展趨勢及發(fā)展前景研究報告
- 在線教育平臺學(xué)員注冊流程分析
- 2025-2030中國番瀉葉行業(yè)市場發(fā)展分析及發(fā)展趨勢與投資戰(zhàn)略研究報告
- 2025-2030中國生鮮電商行業(yè)市場深度分析及發(fā)展趨勢與投資研究報告
- 2025-2030中國狗安全帶行業(yè)市場發(fā)展趨勢與前景展望戰(zhàn)略研究報告
- 汽車配件銷售合同
- 米、面制品安全生產(chǎn)與管理考核試卷
- 資金過橋合同協(xié)議
- 2025年江蘇省連云港市東??h中考英語一模試卷
- 2024年山東青島職業(yè)技術(shù)學(xué)院招聘筆試真題
- 2025-2030國內(nèi)智能玩具行業(yè)市場發(fā)展現(xiàn)狀及競爭策略與投資發(fā)展研究報告
- 倉庫操作規(guī)程試題及答案
- 2025履約類保函擔(dān)保合同范本
- 2025年03月河北邯鄲武安市事業(yè)單位春季博碩人才引進(jìn)55名筆試歷年典型考題(歷年真題考點)解題思路附帶答案詳解
- 水土保持監(jiān)測技術(shù)規(guī)范解讀與應(yīng)用
- 2024年記者證考試時事新聞處理試題及答案
- 廣東省深圳市龍華區(qū)2023-2024學(xué)年七年級下學(xué)期期中英語試卷(含答案)
評論
0/150
提交評論